NeoGenomics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
NeoGenomics, Inc. (NEO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $6.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-17
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $2.10M, a 24.07% increase year-over-year.
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $25.56M.
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-06-30 was $5.54M.
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $6.58M, a 72.66% decline year-over-year.
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $6.40M, a 936.79% increase from fiscal 2024.
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $617.00K, a 91.80% decline from fiscal 2023.
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $7.52M, a 17.81% decline from fiscal 2022.
- NeoGenomics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $9.15M, a 77.00% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.40M 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $617.00K 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $7.52M 10-K · filed 2026-02-17 | |||
| 2022-12-31 | $9.15M 10-K · filed 2024-02-20 | |||
| 2021-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $27.66M derived: sum of 2 quarters · filed 2023-02-24 | $33.20M derived: sum of 3 quarters · filed 2023-02-24 | $39.78M 10-K · filed 2023-02-24 |
| 2021-09-30 | $25.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $31.10M derived: sum of 2 quarters · filed 2021-11-04 | $37.68M 10-Q · filed 2021-11-04 | $39.38M derived: sum of 4 quarters · filed 2022-02-25 |
| 2021-06-30 | $5.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $12.13M 10-Q · filed 2021-08-09 | $13.82M derived: sum of 3 quarters · filed 2022-02-25 | $13.52M derived: sum of 4 quarters · filed 2022-02-25 |
| 2021-03-31 | $6.58M 10-Q · filed 2021-05-06 | $8.28M derived: sum of 2 quarters · filed 2022-02-25 | $7.97M derived: sum of 3 quarters · filed 2022-02-25 | $7.97M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.39M derived: sum of 2 quarters · filed 2022-02-25 | $1.39M derived: sum of 3 quarters · filed 2022-02-25 | $25.46M 10-K · filed 2022-02-25 |
| 2020-09-30 | -$305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$305.00K derived: sum of 2 quarters · filed 2021-11-04 | $23.77M 10-Q · filed 2021-11-04 | $25.52M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $24.07M 10-Q · filed 2021-08-09 | $25.82M derived: sum of 3 quarters · filed 2021-08-09 | $26.60M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $24.07M 10-Q · filed 2021-05-06 | $25.82M derived: sum of 2 quarters · filed 2021-05-06 | $26.60M derived: sum of 3 quarters · filed 2021-05-06 | $33.99M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.53M derived: sum of 2 quarters · filed 2021-02-25 | $9.92M derived: sum of 3 quarters · filed 2021-02-25 | $21.09M 10-K · filed 2021-02-25 |
| 2019-09-30 | $778.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $8.17M derived: sum of 2 quarters · filed 2020-10-29 | $19.34M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $7.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $18.56M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $11.17M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |